A landmark ICMR study confirms that the new six-month oral regimens (BPaL/BPaLM) for drug-resistant TB are not only clinically effective but also cost-effective, saving lives and reducing the economic burden on patients and the health system. This is critical for India's goal to eliminate TB by 2025, as it directly tackles high treatment dropouts and catastrophic health expenditures associated with the older, longer, injectable regimens.
Exam Lens
Quick Exam Facts From News
1-Minute Revision
- ›New Treatment Duration: 6 months
- ›Old Treatment Duration: 9-20 months
- ›Target this Data: ~64,000 MDR-TB cases reported in India in 2023 (approx. 1/3rd of global burden).
- ›Target this Nodal Body: Indian Council of Medical Research - National Institute for Research in Tuberculosis (ICMR-NIRT).
- ›Target this Policy: Shorter 6-month oral regimens (BPaL/BPaLM) introduced in India's National TB Programme in 2024.
Mastered this topic? Test your knowledge with a full MCQ quiz.
Practice exam-style questions, track your score, and strengthen your recall.